dc.contributor.author |
Outhoff, Kim
|
|
dc.date.accessioned |
2011-05-19T08:03:02Z |
|
dc.date.available |
2011-05-19T08:03:02Z |
|
dc.date.issued |
2011-03 |
|
dc.description.abstract |
The human epidermal growth factor receptor 2 (HER2) is overexpressed in HER2-positive breast cancer. This confers characteristics associated with an overall poor prognosis, with early metastases to major visceral sites and a relative resistance to chemotherapy. Trastuzumab is a humanised monoclonal therapeutic antibody that specifically targets HER2 receptor overexpressing breast cancer cells, inhibiting their growth and proliferation, and inducing their regression. It is licensed for metastatic and early HER2-positive breast cancer, determined by slide-based testing techniques. Trastuzumab dosing regimens are aimed at increasing its efficacy, while minimising its potentially undesirable effects which include cardiotoxicity and the development of resistance. |
en_US |
dc.identifier.citation |
Outhoff, K 2011, 'The art of prescribing trastuzumab for HER2-positive breast cancer', South African Journal of Gynaecological Oncology, vol. 3, no. 1, pp.16-26. [http://www.sajgo.co.za/index.php/sajgo/article/view/47/pdf_35] |
en_US |
dc.identifier.issn |
2074-2835 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/16585 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
OpenJournals Publishing |
en_US |
dc.rights |
OpenJournals Publishing |
en_US |
dc.subject |
HER2-positive breast cancer |
en_US |
dc.subject |
Trastuzumab |
en_US |
dc.subject |
Patient eligibility |
en_US |
dc.subject |
Tolerability |
en_US |
dc.subject |
Dosing regimens |
en_US |
dc.subject |
Resistance |
en_US |
dc.subject.lcsh |
Breast -- Cancer -- Treatment |
en |
dc.title |
The art of prescribing trastuzumab for HER2-positive breast cancer |
en_US |
dc.type |
Article |
en_US |